Beckman Coulter and Fujirebio Join Forces to Improve Accessibility of a User-Friendly Blood-Based Test for Alzheimer's Disease
Tuesday, July 18, 2023
Beckman Coulter Diagnostics and Fujirebio have recently announced a strategic partnership to address the growing challenges associated with neurodegenerative diseases, particularly Alzheimer's disease. The two companies will combine their expertise in immunoassay technology to support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in this field.
Neurological disorders are increasingly recognized as a global public health challenge, and their prevalence is expected to rise in the coming decades. Alzheimer's Disease International estimates that over 55 million people worldwide currently live with dementia, and this number is projected to reach 139 million by 2050. With more than 100 disease-modifying drug candidates in development, the pipeline for new therapeutics is promising.
The partnership between Beckman Coulter and Fujirebio is crucial given the intersection of the growing prevalence of neurodegenerative diseases and advancements in disease-modifying therapies, such as the recent FDA approval of monoclonal antibody-based treatments for Alzheimer's disease. By leveraging Fujirebio's expertise in developing neurodegenerative disease biomarker assays and generating clinical evidence, along with Beckman Coulter's high-sensitivity detection capabilities and extensive immunoassay analyzer infrastructure, the collaboration aims to enhance global availability and support the development of more accurate diagnostic solutions.
In addition to the current diagnostic methods that rely on PET imaging or lumbar puncture for cerebral spinal fluid testing, the partnership aims to expand access to patient-friendly, blood-based diagnostic capabilities. By doing so, they hope to complement and accelerate the impact of breakthrough Alzheimer's disease therapeutics. The collaboration with Beckman Coulter will facilitate the deployment of Fujirebio's portfolio of novel neurodegenerative biomarkers to laboratories and clinicians worldwide.
Both companies are committed to bringing a higher standard of care to patients and their families in the battle against Alzheimer's disease. By combining their strengths and leveraging Beckman Coulter's position as a leading provider of immunoassays, the partnership aims to expedite the transition of these biomarkers from research to clinical use, enabling widespread clinical adoption in major regions across the globe.